Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : JDRF
Deal Size : Undisclosed
Deal Type : Partnership
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
Details : The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific T cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : JDRF
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : NEXI-004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NEXI-004 is a patient derived stem cell developed using adoptive cell therapy modality technology which is being developed for EBV associated diseases. It is currently in preclinical stage of development.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : NEXI-004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Oropharyngeal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to Epstein-Barr virus (EBV) and Human T-cell Leukemia Virus, type 1 (HTLV-1).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : KBI Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy option...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : KBI Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : NEXI-003
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : NEXI-003
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : JDRF
Deal Size : $0.6 million
Deal Type : Partnership
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
Details : The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinical model by combining anti-CD3 mAb treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Undisclosed,Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : JDRF
Deal Size : $0.6 million
Deal Type : Partnership
Lead Product(s) : AIM ACT
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Columbia University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma.
Product Name : AIM ACT
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : AIM ACT
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Columbia University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Laura and Isaac Perlmutter Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
Details : The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Laura and Isaac Perlmutter Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NEXI-001,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease has been selected for an oral presentation at the 62nd ASH Annual Meeting.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 04, 2020
Lead Product(s) : NEXI-001,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable